Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells

Li, Yingwei; Guo, Haiyang; Wang, Zixiang; Bu, Hualei; Wang, Shourong; Wang, Hao; Fang, Hongda; Liu, Zhaojian; Kong, Beihua

doi:10.1016/j.yexcr.2020.112212

Cited by 29 publications

(29 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, many are overexpressed in ovarian cancer and are reported to correlate with poor prognosis. These include: SKP2 [ 127 ], PLK1 [ 127 ], CCNB1 [ 127 , 222 ], CDC25B [ 222 ], CEP55 [ 222 ], CENPF [ 222 ], TOP2A [ 222 ], CCNF [ 223 ], PRC1 [ 223 ], and MMP2 [ 222 ]. In addition, several novel FOXM1 gene targets have been identified in ovarian cancer.…”

Section: Foxm1 Oncogenic Functionsmentioning

confidence: 99%

“…For example, the cytoskeleton proteins cytokeratin-5 ( KRT5 ) and cytokeratin-7 ( KRT7 ) are known to promote migration in SKOV3 cells [ 226 ]. DLX1 [ 224 ], PCLAF [ 225 ], KIF20A [ 223 ], and CTNNB1 [ 229 ] have been shown to contribute to proliferation and metastatic phenotypes. Moreover, FOXM1 target genes can be linked to broader cancer pathways.…”

Section: Foxm1 Oncogenic Functionsmentioning

confidence: 99%

“…FOXM1 transcriptional targets linked to platinum resistance in ovarian cancer include exonuclease 1 (EXO1) [ 232 ], a DNA repair protein recruited to double-stranded breaks, and PCLAF [ 225 ], a protein that activates the PI3K/AKT/mTOR signaling pathway. In addition, Protein regulator of cytokinesis-1 (PRC1), which promotes proliferation, migration, and invasion, is a direct FOXM1 transcriptional target found to promote resistance to multiple agents (cisplatin, taxol, and doxorubicin) [ 223 ]. Finally, olaparib treatment of EOC cells stimulated FOXM1 binding to the promoters of CCNB1 [ 233 ], BRCA1 [ 233 , 234 ], BRCA2.…”

Section: Foxm1 Oncogenic Functionsmentioning

confidence: 99%

See 2 more Smart Citations

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

Liu

Barger

Karpf

2021

Cancers

View full text Add to dashboard Cite

Forkhead box M1 (FOXM1) is a member of the conserved forkhead box (FOX) transcription factor family. Over the last two decades, FOXM1 has emerged as a multifunctional oncoprotein and a robust biomarker of poor prognosis in many human malignancies. In this review article, we address the current knowledge regarding the mechanisms of regulation and oncogenic functions of FOXM1, particularly in the context of ovarian cancer. FOXM1 and its associated oncogenic transcriptional signature are enriched in >85% of ovarian cancer cases and FOXM1 expression and activity can be enhanced by a plethora of genomic, transcriptional, post-transcriptional, and post-translational mechanisms. As a master transcriptional regulator, FOXM1 promotes critical oncogenic phenotypes in ovarian cancer, including: (1) cell proliferation, (2) invasion and metastasis, (3) chemotherapy resistance, (4) cancer stem cell (CSC) properties, (5) genomic instability, and (6) altered cellular metabolism. We additionally discuss the evidence for FOXM1 as a cancer biomarker, describe the rationale for FOXM1 as a cancer therapeutic target, and provide an overview of therapeutic strategies used to target FOXM1 for cancer treatment.

show abstract

Section: Foxm1 Oncogenic Functionsmentioning

confidence: 99%

Section: Foxm1 Oncogenic Functionsmentioning

confidence: 99%

Section: Foxm1 Oncogenic Functionsmentioning

confidence: 99%

See 1 more Smart Citation

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

Liu

Barger

Karpf

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…S2a and S2b). FOXM1 has an effect on the biological functions of various cancers through synergistic interactions or transcriptional regulation with CENPF [36][37][38] and KIF20A [39][40][41]. Because FOXM1 has a strong correlation and synergistic interaction or transcriptional regulation with CENPF and KIF20A, we selected FOXM1 as the main gene for the following experiment.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA SH3PXD2A-AS1 promotes NSCLC proliferation and accelerates cell cycle progression by interacting with DHX9

Zhou

Yong

Chu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background As the most commonly diagnosed lung cancer, non–small cell lung carcinoma (NSCLC) is regulated by many long noncoding RNAs (lncRNAs). In the present study, we found that SH3PXD2A-AS1 expression in NSCLC tissues was upregulated compared with that in normal lung tissues in The Cancer Genome Atlas (TCGA) database. However, the role and molecular mechanism of SH3PXD2A-AS1 in NSCLC progression require further exploration. Methods The expression of SH3PXD2A-AS1 in NSCLC and normal lung tissues in a TCGA dataset was analysed by using the GEPIA website. K-M analysis was performed to explore the effects of this molecule on the survival rate in NSCLC. The functional characterization of the role and molecular mechanism of SH3PXD2A-AS1 in NSCLC was performed with a series of in vitro and in vivo experiments. Results SH3PXD2A-AS1 expression was increased in human NSCLC, and high SH3PXD2A-AS1 expression was correlated with poor overall survival. SH3PXD2A-AS1 overexpression sufficiently promoted tumour cell proliferation and accelerated cell cycle progression in vitro and tumour growth in vivo. Moreover, SH3PXD2A-AS1 interacted with DHX9 to enhance FOXM1 expression, promote tumour cell proliferation and accelerate cell cycle progression. Conclusions SH3PXD2A-AS1 promoted NSCLC growth by interacting with DHX9 to enhance FOXM1 expression. SH3PXD2A-AS1 may serve as a promising predictive biomarker for the diagnosis and prognosis of patients with NSCLC.

show abstract

“…Until now, KIF20A has been reported to be a key gene in the progression of many tumors, such as prostate cancer, colorectal cancer, gastric cancer, et al [48][49][50]. Recently, KIF20A has also been proved to promote the invasion and metastasis of EOC, and could be seen as a valuable chemoresistance and prognostic biomarker for EOC patients [51][52][53].…”

Section: Kegg and Go Pathway Analysis For 5 Core Genesmentioning

confidence: 99%

Identification of potential markers for differentiating epithelial ovarian cancer from ovarian low malignant potential tumors through integrated bioinformatics analysis

Hao

Zhao

et al. 2021

J Ovarian Res

View full text Add to dashboard Cite

Background Epithelial ovarian cancer (EOC), as a lethal malignancy in women, is often diagnosed as advanced stages. In contrast, intermediating between benign and malignant tumors, ovarian low malignant potential (LMP) tumors show a good prognosis. However, the differential diagnosis of the two diseases is not ideal, resulting in delays or unnecessary therapies. Therefore, unveiling the molecular differences between LMP and EOC may contribute to differential diagnosis and novel therapeutic and preventive policies development for EOC. Methods In this study, three microarray data (GSE9899, GSE57477 and GSE27651) were used to explore the differentially expressed genes (DEGs) between LMP and EOC samples. Then, 5 genes were screened by protein–protein interaction (PPI) network, receiver operating characteristic (ROC), survival and Pearson correlation analysis. Meanwhile, chemical-core gene network construction was performed to identify the potential drugs or risk factors for EOC based on 5 core genes. Finally, we also identified the potential function of the 5 genes for EOC through pathway analysis. Results Two hundred thirty-four DEGs were successfully screened, including 81 up-regulated genes and 153 down-regulated genes. Then, 5 core genes (CCNB1, KIF20A, ASPM, AURKA, and KIF23) were identified through PPI network analysis, ROC analysis, survival and Pearson correlation analysis, which show better diagnostic efficiency and higher prognostic value for EOC. Furthermore, NetworkAnalyst was used to identify top 15 chemicals that link with the 5 core genes. Among them, 11 chemicals were potential drugs and 4 chemicals were risk factors for EOC. Finally, we found that all 5 core genes mainly regulate EOC development via the cell cycle pathway by the bioinformatic analysis. Conclusion Based on an integrated bioinformatic analysis, we identified potential biomarkers, risk factors and drugs for EOC, which may help to provide new ideas for EOC diagnosis, condition appraisal, prevention and treatment in future.

show abstract

Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells

Cited by 29 publications

References 40 publications

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

Long noncoding RNA SH3PXD2A-AS1 promotes NSCLC proliferation and accelerates cell cycle progression by interacting with DHX9

Identification of potential markers for differentiating epithelial ovarian cancer from ovarian low malignant potential tumors through integrated bioinformatics analysis

Contact Info

Product

Resources

About